DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

company name or ticker

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Orexigen Therapeutics Retains Prescribers' And Analysts' Support

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Which of These Growth Stocks Is Most Worthy of Your Money?

Amarin Corp. and Arena Pharmaceuticals were once high-flying biotech stocks. Since the commercial launch of their respective flagship products, though, their shares have fallen in a big way. In this article, I consider which stock has the better chance of recapturing its former glory going forward.

Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More

Orexigen Therapeutics: Problems Associated With Early Data Release

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog

Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog

Are Problems at Orexigen Still Just Getting Started?

See More Articles...